## Stakeholder Engagement - Section 172 Statement

For more than a century, MSD has been at the forefront of research, bringing forward medicines, vaccines, and innovative health solutions for the world's most challenging human and animal diseases. Through inclusive scientific research, enabling access to ground-breaking treatments and effective partnerships with the health system, we believe that we can cultivate a more equitable healthcare landscape that is equipped to make a real difference to patients' lives and ultimately, tip the scales on health disparities in the UK.

What we do and how we do it matters. Our values are our core: putting patients first, respect for people, ethics and integrity and innovation and scientific excellence. Our Code of Conduct enables our employees to operate with the highest levels of integrity at every level throughout our organisation.

The table below identifies our key stakeholders and how we have engaged with them throughout 2022.

Stakeholder Group	Interests	Business and Director Engagement
	What are their key interests? What issues and factors are important to them?	How did the business and its' directors engage with this stakeholder in 2021?
Regulatory Bodies	<ul> <li>Compliance with Medicines and Controlled Drug Regulations</li> <li>Reviewing, evaluating, and approving applications for Investigational Medical Products (IMP) and Non-IMP clinical trials</li> <li>Sets standards for interactions between industry and health professionals</li> <li>Protect and promote the interests of patients and the public in health and social care</li> <li>Compliance with financial reporting regulations</li> </ul>	<ul> <li>Timely submission of high quality and accurate documentation</li> <li>Direct, open and transparent engagement on inspections, audits and enquiries (internal and external)</li> <li>Through industry associations, industry association boards, forums, conferences and meetings</li> </ul>
Patients	<ul> <li>Promote the patient voice in order to improve patients' experience of healthcare</li> <li>Access to safe and efficacious medicine</li> <li>Minimal burden associated with clinical trial participation</li> </ul>	<ul> <li>Engaged directly (meetings, membership, social media and events), as well as indirectly (through industry associations) to ensure the development of any solution, treatment, or digital strategy is patient-centric</li> <li>Indirect engagement through clinical trial participation and data collection.</li> </ul>
Government and Payers	<ul> <li>Set the policies, rules, regulations and operating environment for life sciences, health and medicines</li> <li>Responsible for providing evidence-based guidance on health and social care</li> <li>Ensure accountability of the health and care system to Parliament and the taxpayer</li> <li>Support the NHS to deliver high quality, safe and sustainable care.</li> </ul>	<ul> <li>Directly through meetings and written submissions to inquiries and consultations. Indirectly through industry associations</li> <li>Enable our product for the benefit of the patient through HTA and Regulatory approvals and supply to the markets in line with the contracts with government bodies</li> <li>Indirect engagement via industry (ABPI) association boards</li> </ul>

Stakeholder	Interests	Business and Director Engagement
Group		
	What are their key interests?	How did the business and its' directors
	What issues and factors are	engage with this stakeholder in 2021?
	important to them?	
Health Care	Accurate and up-to-date Medical	<ul> <li>Provision of Medical Information in</li> </ul>
Practitioners	Information on licensed products	response to individual, unsolicited
(HCP's) and	<ul><li>Collaboration, Joint Working and</li></ul>	enquiries
Health Care	Sharing of Information	Engagement as consultants to address
Organisations	Health and high quality care for	company knowledge gaps via advisory
(HCO's)	all Advancing science by providing	boards or as speakers for medical education activities
(1100 3)	modern medicine to patients to	Provision of medical education via
	address unmet medical needs	resources and meetings, including
		congress attendance
		<ul> <li>Collaborative working, including Joint</li> </ul>
		Working Projects and proactive Medical
		Educational Goods and Services
		(MEGS). ➤ Promotion of MSD Medicines
		Promotion of wisd wiedicines
Our People	<ul> <li>Values, standards and Ways of</li> </ul>	➤ Regular Town Halls – globally,
Our People	Working (WOW)	regionally and locally
	Competitive and fair	➤ Intranet and email weekly round up
	compensation, benefits, flexible	communications across all UK sites
	working, training and	Quaterly employee listening surveys
	development opportunities	Employee Representative Committees
	<ul> <li>Diversity and Inclusion</li> <li>Wellbeing, Health and Safety</li> </ul>	<ul> <li>Office of Ethics - safe to speak up environment</li> </ul>
	Wellbeing, Health and Safety	Employee listening circles
		Employee listerling circles
Suppliers	<ul><li>Understanding of MSD's strategy</li></ul>	Partner/sponsor with organisations that
Cappilois	and how the supplier can best	promote supplier diversity
	create economic, social and	<ul> <li>Engage collaboratively at a regional and</li> </ul>
	environmental value through	global level to leverage enterprise-wide
	innovation and business	supplier relationships
	partnering	Work closely with the business to
	<ul> <li>Creating a collaborative and trusting environment between</li> </ul>	identify current and future needs and
	the supplier and MSD	identify suppliers that can service these requirements
	➤ That MSD acts ethically and	<ul><li>Supplier Relationship management -</li></ul>
	have open and transparent	manage and develop relationships that
	processes	meet mutual long-term business
	Economic inclusion that supports	objectives
	supplier diversity	